The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
179 reports and counting
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Slingshot Biosciences Appoints Dr. Nimisha Srivastava CEO
Slingshot Biosciences promoted Chief Operating Officer Dr. Nimisha Srivastava to CEO to lead commercial growth and product development.
Claris Bio Relocates Corporate Headquarters to South San Francisco
Claris Bio will relocate its corporate headquarters from Jersey City to South San Francisco in October 2026 as it advances CSB-001.
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
NovaGo Therapeutics Raises $30M Series B for Spinal Cord Injury Study
NovaGo Therapeutics raised a $30 million Series B led by Neurimmune and Pureos Bioventures to advance a proof-of-concept study in acute spinal cord injury.
AusperBio Raises $120M Series C for Hepatitis B Oligonucleotide Therapies
AusperBio closed a $120 million Series C led by a strategic investor, with new investor RA Capital participating, to advance its hepatitis B candidate AHB-137.
Infinimmune Raises $75M Series A for Human-Derived Antibody Drugs
Infinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance human-derived antibody programs in atopic dermatitis and inflammatory disease.
Aureka Biotechnologies Raises $100M Series B for Biological Foundation Models
Aureka Biotechnologies closed a $100 million Series B to train biological foundation models and expand its experiment-centered drug-discovery platform.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.